The Clinical Characteristics, Treatment and Prognosis of Tuberculosis-associated Chronic Obstructive Pulmonary Disease: A Protocol for a Multicenter Prospective Cohort Study in China

Author:

Jiang Zhihan1,Dai Yingying2,Chang Jing2,Xiang Pingchao3,Liang Zhenyu4,Yin Yan5,Shen Yongchun6,Wang Ruiying7,Qiongda Bianba8,Chu Hongling9,Li Nan9,Gai Xiaoyan1,Liang Ying1,Sun Yongchang1

Affiliation:

1. Department of Respiratory and Critical Care Medicine, Peking University Third Hospital

2. School of Basic Medical Sciences, Peking University

3. Department of Respiratory and Critical Care Medicine, Peking University Shougang Hospital

4. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health

5. Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University

6. Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University

7. Department of Respiratory and Critical Care Medicine, Shanxi Bethune Hospital

8. Department of Respiratory and Critical Care Medicine, Tibet Autonomous Region People’s Hospital

9. Clinical Epidemiology Research Center, Peking University Third Hospital

Abstract

Abstract Background Both tuberculosis and COPD are major public health problems and pulmonary tuberculosis has been confirmed as an important risk factor for COPD. Tuberculosis participates in the development of COPD through distinctive pathophysiological mechanisms. Tuberculosis-associated COPD is a unique phenotype of COPD and may have distinct characteristics compared to COPD patients without previous tuberculosis history. The precise definition, clinical characteristics, prognosis and optimal pharmacologic intervention of tuberculosis-associated COPD warrant further investigation. Methods This multicenter, prospective, observational cohort study will recruit more than 135 tuberculosis-associated COPD and 405 non-tuberculosis-associated COPD patients aged 35 years or older from 7 tertiary hospitals across mainland China. Diagnosis of tuberculosis-associated COPD is made if any of the following criteria is met: (1) previously definite pulmonary tuberculosis and ever receiving standard antituberculosis therapy; (2) previously suspected pulmonary tuberculosis and having typical radiological findings consistent with tuberculosis sequelae; (3) no definite history of pulmonary tuberculosis but having positive results of interferon gamma release assays accompanied with typical radiological signs. Demographic data, medical history related to COPD, respiratory questionnaires, blood routine examination, interferon gamma release assays, therapeutic regimen, lung function and chest CT will be collected at baseline. Patients will be followed up for 1 year and evaluated at outpatient every 6 months to record the longitudinal changes of symptoms, treatment regimen, lung function and frequency of exacerbation and hospitalization due to COPD. Furthermore, patients can consult their physicians whenever their symptoms get worse. Chest CT and total medical expenditure will be additionally assessed in the last outpatient visit. The study has been approved by Peking University Third Hospital Medical Science Research Ethics Committee (approval number: IRB00006761-M2023573). Discussion This study will provide a detailed characteristic profile of tuberculosis-associated COPD and propose potential treatment options for this specific patient group. Trial registration Registration number in ClinicalTrials.gov: NCT06074042

Publisher

Research Square Platform LLC

Reference45 articles.

1. Global strategy for. the diagnosis, management and prevention of chronic obstructive pulmonary disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2022 report. Available from: http://www.goldcopd.org/. Accessed November 14, 2022.

2. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019;Safiri S;BMJ

3. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017;Soriano JB;Lancet Resp Med,2020

4. Dheda K, Barry CE 3rd, Maartens G. Tuberculosis Lancet. 2016;387:1211–26.

5. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis;Fan H;Ann Transl Med,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3